SAGIMET BIOSCIENCES INC-A (SGMT)
US7867001049 - Common Stock
SGMT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. While SGMT has a great health rating, there are worries on its profitability. SGMT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SGMT had negative earnings in the past year.
SGMT had a negative operating cash flow in the past year.
In the past 5 years SGMT always reported negative net income.
SGMT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -28.83%, SGMT is in the better half of the industry, outperforming 70.05% of the companies in the same industry.
SGMT's Return On Equity of -30.62% is fine compared to the rest of the industry. SGMT outperforms 79.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.83% | ||
| ROE | -30.62% | ||
| ROIC | N/A |
ROA(3y)-54.19%
ROA(5y)-61.37%
ROE(3y)-61.4%
ROE(5y)-72.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SGMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SGMT has been increased compared to 1 year ago.
There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 14.70 indicates that SGMT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 14.70, SGMT belongs to the best of the industry, outperforming 89.48% of the companies in the same industry.
There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.7 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 17.09 indicates that SGMT has no problem at all paying its short term obligations.
SGMT's Current ratio of 17.09 is amongst the best of the industry. SGMT outperforms 90.73% of its industry peers.
SGMT has a Quick Ratio of 17.09. This indicates that SGMT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 17.09, SGMT belongs to the best of the industry, outperforming 90.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.09 | ||
| Quick Ratio | 17.09 |
3. Growth
3.1 Past
The earnings per share for SGMT have decreased strongly by -87.67% in the last year.
EPS 1Y (TTM)-87.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, SGMT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.12% on average per year.
Based on estimates for the next years, SGMT will show a very strong growth in Revenue. The Revenue will grow by 115.67% on average per year.
EPS Next Y90.62%
EPS Next 2Y33.4%
EPS Next 3Y18.63%
EPS Next 5Y11.12%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y115.67%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SGMT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SGMT's earnings are expected to grow with 18.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.4%
EPS Next 3Y18.63%
5. Dividend
5.1 Amount
No dividends for SGMT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SAGIMET BIOSCIENCES INC-A
NASDAQ:SGMT (11/4/2024, 8:00:02 PM)
After market: 5.38 -0.04 (-0.74%)5.42
+0.09 (+1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap174.52M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.83% | ||
| ROE | -30.62% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 17.09 | ||
| Quick Ratio | 17.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-87.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y90.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y